D. Boral Capital Has Lowered Expectations for Invivyd (NASDAQ:IVVD) Stock Price

Key Points

• D. Boral Capital has significantly lowered its price target for Invivyd (IVVD) from $9.00 to $3.00, while maintaining a "buy" rating on the stock.
• HC Wainwright also reiterated a "buy" rating but set a higher, separate price target of $5.00 for the shares.
• Invivyd's recent financial performance showed a missed earnings estimate, reporting a loss of $0.12 per share against a consensus of a $0.04 loss, alongside a negative net margin of 389.01%.

Invivyd (NASDAQ:IVVD - Get Free Report) had its price objective reduced by research analysts at D. Boral Capital from $9.00 to $3.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. D. Boral Capital's target price would suggest a potential upside of 275.33% from the company's previous close.

Separately, HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Invivyd in a research report on Thursday, June 26th.

Invivyd Price Performance

Shares of IVVD stock opened at $0.80 on Friday. Invivyd has a 12-month low of $0.35 and a 12-month high of $2.74. The firm has a market capitalization of $95.88 million, a price-to-earnings ratio of -0.67 and a beta of 0.51. The business has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $0.83.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. On average, equities analysts anticipate that Invivyd will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently bought and sold shares of IVVD. Catalyst Funds Management Pty Ltd acquired a new position in Invivyd during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC increased its position in Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock worth $29,000 after buying an additional 28,146 shares during the last quarter. Jane Street Group LLC increased its position in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC increased its position in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after buying an additional 9,207 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Invivyd during the first quarter worth $65,000. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.